14 Results for "

DSPE-PEG2000-triGalNAc

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "DSPE-PEG2000-triGalNAc" in MCE Product Catalog:

Cat. No.: HY-157950
CAS No.: 2936651-86-2
Target:  

Liposome

Research Areas:  

Cancer

DSPE-PEG2K-triGalNAc ammonium is a polar lipid composed of DSPE and tri-N-acetylgalactosamine that can be used to construct liposomes target to asialoglycoprotein receptor (ASGPR).
loading...
    loading...
Cat. No.: HY-P10392AF
Target:  

Wnt β-catenin

Research Areas:  

Cancer

fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
loading...
    loading...
Cat. No.: HY-P10896
CAS No.: 1446005-10-2
Target:  

Bombesin Receptor

Research Areas:  

Cancer

NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
loading...
    loading...
Cat. No.: HY-169232
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Cancer

PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers .
loading...
    loading...
Cat. No.: HY-P5045
CAS No.: 133575-43-6
Research Areas:  

Inflammation/Immunology Cancer

Fmoc-Thr(GalNAc(Ac)3-β-D)-OH inhibits cancer cell growth, through targeting intricate cancer-specific pathways while simultaneously strengthening immunologic response .
loading...
    loading...
Cat. No.: HY-P5511
CAS No.: 869012-68-0
Target:  

Inhibitory Antibodies

Research Areas:  

Others

MUC5AC-3/13 is a biological active peptide. (glycopeptide transferase, ppGaNTase-T9 substrate)
loading...
    loading...
Cat. No.: HY-P5508
CAS No.: 869012-67-9
Target:  

Inhibitory Antibodies

Research Areas:  

Others

MUC5AC-13 is a biological active peptide. (This glycopeptide is an N-acetyl galactosamine (GalNAc)-modified MUC5AC mucin peptide containing the single site of threonine 13 labeled with GalNAc (T*). Polypeptide N-acetylgalactosaminyltransferase (ppGaNTase) catalyzes the transfer of GalNAc from the nucleotide sugar UDP-GalNAc to threonine. The MUC5AC gene is mainly expressed in gastric and tracheo-bronchial mucosae, and some tumors.)
loading...
    loading...
Cat. No.: HY-P5512
CAS No.: 869012-66-8
Target:  

Inhibitory Antibodies

Research Areas:  

Others

MUC5AC-3 is a biological active peptide. (glycopeptide transferase, ppGaNTase-T9 substrate)
loading...
    loading...
Cat. No.: HY-P12133
CAS No.: 3080063-21-1
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Tapimtrutide is a gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Tapimtrutide can be used for the research of diabetes .
loading...
    loading...
Cat. No.: HY-P11625
Target:  

RXFP Receptor

Research Areas:  

Cardiovascular Disease

R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
loading...
    loading...
Cat. No.: HY-P11830
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-P11596
CAS No.: 3107808-75-0
Target:  

Integrin

Research Areas:  

Cancer

NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Cat. No.: HY-P11846
Target:  

ADAMTS

Research Areas:  

Cardiovascular Disease

ADA2 is an ADAMTS4-binding peptide and imaging agent with a human ADAMTS4 Ka of 5.3 nM and reduced renal uptake compared to related tracers. ADA2 accumulates in dilated aortic regions in aortic aneurysm mouse models. ADA2 exhibits an in vivo safety profile. ADA2 can be used for the research of aortic aneurysm .
loading...
    loading...
Cat. No.: HY-P3252AS
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
loading...
    loading...
  • 1